Heitrin

Heitrin is a prescription medication that contains the active ingredient Terazosin Hydrochloride Dihydrate. It is formulated for oral administration and belongs to the selective alpha‑1 adrenergic blocker class. Heitrin is marketed in the European Union and is used under medical supervision to manage high blood pressure and symptoms associated with benign prostatic hyperplasia (BPH).

Heitrin is indicated for two primary therapeutic areas, providing clinicians with a single agent for related conditions.

- Management of hypertension by reducing peripheral vascular resistance. - Relief of urinary obstruction symptoms caused by benign prostatic hyperplasia. - Adjunct therapy in patients with coexisting hypertension and BPH. - Long‑term blood pressure control when lifestyle measures are insufficient. - Use in patients who require a once‑daily oral alpha‑1 blocker.

Side effects of Heitrin vary in frequency and severity. Patients should be aware of both common and less frequent reactions.

Common: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or tiredness. - Nasal congestion. - Swelling of the ankles or feet. - Nausea.

Serious: - Severe hypotension leading to fainting. - Priapism (prolonged erection). - Persistent or worsening urinary retention. - Allergic reactions such as rash, itching, or swelling of the face. - Rapid heart rate (tachycardia).

Before starting Heitrin, certain health considerations should be reviewed to minimize risks.

- Assess baseline blood pressure and monitor for orthostatic changes. - Evaluate renal and hepatic function, as dosage adjustments may be needed. - Use caution in patients with a history of cardiovascular disease or heart failure. - Discuss any history of prostate surgery or severe urinary obstruction. - Inform the prescriber about all current medications, including over‑the‑counter products. - Pregnant or breastfeeding individuals should consult a healthcare professional before use. - Discontinue use gradually under medical guidance to avoid rebound hypertension.

Heitrin can interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Other antihypertensive agents (e.g., beta‑blockers, ACE inhibitors) that may cause additive blood pressure lowering. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. - Strong CYP3A4 inhibitors that could increase terazosin plasma levels.

Use with caution: - Diuretics, which may enhance orthostatic hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal function. - Medications that prolong the QT interval. - Herbal supplements such as St. John’s wort that induce CYP enzymes.